-+ 0.00%
-+ 0.00%
-+ 0.00%
Matchpoint Therapeutics closes $150 million Series B with T1D Fund participation
Share
Listen to the news
Matchpoint Therapeutics closes $150 million Series B with T1D Fund participation
  • Matchpoint Therapeutics raised USD 150 million in a Series B round co-led by Nextech Invest, Norwest.
  • T1D Fund A Breakthrough T1D Venture LLC participated alongside other new and existing investors.
  • Matchpoint develops precision covalent oral small-molecule drugs for autoimmune, inflammatory diseases.
  • Funding to advance lead program MPT-062, an oral first-in-class T cell modulator, toward clinical proof-of-concept.
  • Company expects MPT-062 to enter clinical development in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. T1D Fund A Breakthrough T1D Venture LLC published the original content used to generate this news brief on October 07, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending